MOTS-c vs Tirzepatide
Related research areas, distinct mechanisms. Live $/mg pricing across every tracked vendor.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
Both surface in metabolic-research conversations — particularly around insulin sensitivity, weight regulation, and obesity-adjacent endpoints.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical weight-loss data. MOTS-c is a 16-residue mitochondrial peptide studied as an exercise mimetic. The mechanisms don't overlap — these are not substitute compounds.
MOTS-c
Mitochondrial exerkine
Tirzepatide
Dual GLP-1/GIP agonist
About MOTS-c
A 16-residue peptide encoded within the mitochondrial 12S rRNA. Studied as an exercise-mimetic exerkine for metabolic health and longevity.
About Tirzepatide
A once-weekly dual GIP and GLP-1 receptor agonist studied for type-2 diabetes and obesity. Approved clinically in many jurisdictions; research-compound form is widely distributed.